- Promotes women’s health with strategically branded personal feminine health test that is simple and discreet
- Updates shareholders on CBD patents for two CBD-based nutraceutical formulas
- Reacts to DEA’s shift on CBD
The new logo and a detailed marketing strategy for ETST’s self-sampling medical device for women to discretely identify sexually transmitted infections was announced on October 9, 2018 (http://ibn.fm/1AVhy). The brand’s name, Hygee, is a play on the Greek word for hygiene. Special care was put into making sure that the logo was memorable, simplistic and clear in identifying the product as a personal feminine health test. The tagline communicates the personal nature of this self-test as accurate, simple and discreet. The product itself looks and is worn like a standard panty liner.
“Hygee is designed to preserve women’s health,” Dr. Michel Aubé, CEO and chief science officer of ETST, stated in a news release. “The best way to fight STIs is prevention, and the only way for women to avoid the dangerous results of untreated STI is early treatment. This means that women need to know if they are infected. We believe that Hygee will be the best tool to provide that information. ETST will target specific populations of women globally to better counter the STI epidemic.”
ETST has plans to market Hygee on five continents. Around the world, there are an estimated 100 million tests for chlamydia trachomatis alone, but none offer the discreet technology of ETST’s Hygee.
In addition to marketing advancements with Hygee, ETST is developing a new brand for the launch of two CBD-based nutraceutical formulas, a neuron protector and a breast protector, under a provisory patent (http://ibn.fm/So0Di). Quebec Agrifood Innovation Center is finishing the standardization of the formulas and, by the end of October, TransBiotech is expected to conduct in vitro testing. The testing will compare the level of protection provided by ETST’s hemp oil alone versus its hemp oil with other natural ingredients.
In a news release, Nickolas Tabraue, ETST’s president and CEO, stated, “The results obtained from TransBiotech will help us understand the mechanism of action of CBD and will open the doors for the research needed to develop revolutionary CDB-based pharmaceutical drugs.”
The DEA recently decided to reclassify FDA-approved drugs that contain cannabis-derived CBD and less than 0.1 percent tetrahydrocannabinol (THC) as schedule V, the lowest restriction classification. This is good news for ETST and will open doors to further develop treatments for other illnesses, make CBD clinical tests easier to plan and provide potential for a worldwide market.
Regarding this new classification, Aubé added, “We are pleased to see that the DEA has shifted its stance amid conclusive evidence that CBD is not addictive but has both anti-psychotic properties and the opposite effect of THC.”
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
